Comparative Pharmacology
Head-to-head clinical analysis: DROPERIDOL versus SPARINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROPERIDOL versus SPARINE.
DROPERIDOL vs SPARINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Droperidol is a butyrophenone antipsychotic that acts primarily as a dopamine D2 receptor antagonist. It also exhibits antiemetic effects via blockade of dopamine D2 receptors in the chemoreceptor trigger zone. Additionally, it has alpha-adrenergic blocking properties and can prolong the QT interval by blocking cardiac potassium channels (hERG).
Phenothiazine antipsychotic; blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors; also blocks alpha-adrenergic receptors, and has anticholinergic and antihistaminergic effects.
2.5-10 mg IV/IM every 3-4 hours as needed for nausea and vomiting; for agitation or psychosis in perioperative settings: 0.625-1.25 mg IV/IM, may repeat every 6 hours.
Promazine hydrochloride: 25-50 mg intramuscularly or intravenously every 4-6 hours as needed; maximum 300 mg/day. Alternatively, oral: 25-200 mg every 4-6 hours; maximum 1000 mg/day. Route and frequency depend on indication and patient response.
None Documented
None Documented
Clinical Note
moderateDroperidol + Norfloxacin
"Droperidol may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateDroperidol + Ibandronate
"Droperidol may increase the QTc-prolonging activities of Ibandronate."
Clinical Note
moderateDroperidol + Indapamide
"Droperidol may increase the QTc-prolonging activities of Indapamide."
Clinical Note
moderateDroperidol + Methylphenidate
"The risk or severity of adverse effects can be increased when Droperidol is combined with Methylphenidate."
Terminal elimination half-life: 2.3 hours (range 1.5–4.7 hours). Clinical context: Short half-life allows rapid titration but requires repeated dosing or continuous infusion for sustained effect; accumulation with hepatic impairment.
Terminal elimination half-life: 10-20 hours; clinical context: allows once or twice daily dosing; extended in elderly and hepatic impairment
Renal (75% as metabolites, <1% unchanged); fecal (22%); biliary excretion contributes to enterohepatic circulation.
Primarily renal (70-80% as metabolites, less than 1% unchanged); biliary/fecal (15-30%)
Category A/B
Category C
Antipsychotic
Antipsychotic